WDFY4

WDFY4 is a BEACH domain-containing protein that serves as an essential, non-redundant intracellular factor for the cross-presentation of exogenous antigens by classical dendritic cells, enabling priming of CD8+ T cells (PMID:30409884). In Batf3-dependent cDC1s, WDFY4 is dispensable for cell development, IL-12 production, and MHC class II presentation, but is specifically required to cross-present cell-associated antigens, prime virus-specific CD8+ T cells, and drive tumor rejection (PMID:30409884). This requirement extends beyond cDC1s: cross-presentation of immune complex antigens by cDC2s is likewise WDFY4-dependent, whereas monocyte-derived DCs cannot substitute in either case (PMID:39918736). The same pathway operates in autoimmunity, where WDFY4-dependent cDC1 cross-presentation is needed to prime autoreactive CD8+ T cells and drive progression of autoimmune diabetes (PMID:36940342). Beyond dendritic cells, WDFY4 acts intrinsically in other immune compartments: it promotes the pro- to pre-B cell transition and antibody responses while facilitating a p62/Beclin1-independent noncanonical autophagy marked by LC3 lipidation (PMID:30257884), supports CD8+ T cell survival and proliferation by restraining ROS/Nox2, p53, and ERK signaling (PMID:34482201), and limits Th2 cell differentiation (PMID:34425575). In innate signaling, WDFY4 and a truncated isoform physically interact with the pattern recognition receptors TLR3, TLR4, TLR9, and MDA5 to augment NF-κB activation and MDA5-induced apoptosis (PMID:29331962). WDFY4 also interacts with LAPTM5 to promote endothelial ferroptosis via a downstream CDC42/mTOR/4EBP1/SLC7A11 axis (PMID:40755163). WDFY4 transcription is controlled by YY1 binding at an intronic disease-associated variant, where the risk allele lowers YY1 affinity and reduces expression (PMID:22972472).

1. 2012 Medium

   Established how a disease-associated noncoding WDFY4 variant alters gene function, showing it is a transcriptional regulatory variant rather than a coding change.

   Evidence EMSA, supershift, dual-luciferase, YY1 knockdown/overexpression, and ChIP at intronic variant rs877819

   PMID:22972472

   Open questions at the time

   • Does not connect altered WDFY4 expression level to a specific cellular phenotype
   • Single-lab characterization of one variant
   • No demonstration that YY1 regulation operates in the relevant immune cell types
2. 2018 High

   Defined WDFY4 as the non-redundant intracellular machinery required specifically for cDC1 cross-presentation, separating this function from cDC1 development and MHC-II presentation.

   Evidence CRISPR functional screen and Wdfy4-/- mice with in vivo cross-presentation, viral CD8+ priming, and tumor rejection assays

   PMID:30409884

   Open questions at the time

   • Molecular mechanism by which WDFY4 enables antigen cross-presentation not resolved
   • No biochemical partners or subcellular trafficking step identified
   • Role of the BEACH domain in this function untested
3. 2018 Medium

   Linked WDFY4 to innate signaling and connected it to autoimmune disease risk by showing direct association with pattern recognition receptors and modulation of downstream responses.

   Evidence Co-IP/interaction assays, NF-κB reporter and apoptosis assays in transfected cells, and trans-eQTL analysis for full-length and truncated isoforms

   PMID:29331962

   Open questions at the time

   • Co-IP/reporter assays in a single lab without reciprocal in vivo validation
   • Interaction domains and mechanism of NF-κB augmentation not mapped
   • Relationship between this innate signaling role and the cross-presentation role unclear
4. 2018 Medium

   Extended WDFY4 function to B cell development and antibody responses and tied it mechanistically to a noncanonical autophagy process.

   Evidence B cell-conditional Wdfy4 knockout mice, flow cytometry, antibody and SLE-model assays, and LC3 lipidation with p62/Beclin1 independence testing

   PMID:30257884

   Open questions at the time

   • Molecular basis of the noncanonical autophagy contribution not defined
   • Single-lab conditional knockout
   • Connection to the cross-presentation pathway not established
5. 2021 Medium

   Identified a T cell-intrinsic role for WDFY4 in CD8+ T cell survival and proliferation, implicating ROS, p53, and ERK signaling.

   Evidence T cell-conditional Wdfy4 knockout mice with tumor challenge, ROS/Nox2 measurement, and p53/ERK pathway analysis

   PMID:34482201

   Open questions at the time

   • Causal ordering between WDFY4, ROS, p53, and ERK not dissected
   • No direct molecular target of WDFY4 identified
   • Single-lab study
6. 2021 Medium

   Showed WDFY4 restrains Th2 differentiation, broadening its immune role to allergic inflammation.

   Evidence Wdfy4-knockout mice with in vitro Th2 differentiation and OVA-induced asthma model with cytokine and histological readouts

   PMID:34425575

   Open questions at the time

   • Mechanism by which WDFY4 limits Th2 polarization not defined
   • Cell-intrinsic versus extrinsic contribution not fully resolved
   • Single-lab study
7. 2025 High

   Demonstrated that WDFY4-dependent cross-presentation is not cDC1-restricted, establishing cDC2 as a sufficient cross-presenting cell for immune complex antigens.

   Evidence cDC1-deficient and Wdfy4-/- mice with in vivo immune complex/cell-associated antigen presentation and tumor rejection assays

   PMID:39918736

   Open questions at the time

   • Molecular determinant of which antigens route through cDC2 versus cDC1 unknown
   • Whether WDFY4 acts identically in cDC1 and cDC2 not established at the mechanistic level
8. 2025 Medium

   Placed WDFY4 in an endothelial ferroptosis pathway through a direct interaction with LAPTM5 upstream of a CDC42/mTOR/4EBP1/SLC7A11 axis.

   Evidence Co-IP, immunofluorescence co-localization, endothelium-specific mouse models, and rescue experiments with LAPTM5 overexpression and CDC42 inhibition

   PMID:40755163

   Open questions at the time

   • Downstream pathway partially inferred rather than fully demonstrated
   • Single-lab Co-IP without reciprocal validation
   • Relationship of this endothelial role to immune cross-presentation function unknown

• The core biochemical mechanism by which WDFY4 enables antigen cross-presentation, and how its BEACH domain and diverse interaction partners coordinate this with its other immune and ferroptotic roles, remains unresolved.
• No structural model or defined enzymatic/scaffolding activity for WDFY4
• No identified molecular step in the cross-presentation pathway that WDFY4 executes
• Unclear whether the distinct reported functions reflect one unifying mechanism or context-specific roles